BACKGROUND: A maternal red blood cell (RBC) folate concentration > 906 nmol/L is thought to be optimal for lowering the risk of neural tube defects (NTDs) in pregnancy. Whereas the appearance of folate in RBCs has been followed during folic acid supplementation, data on elimination kinetics are not yet available. OBJECTIVE: The aim of our investigation was to estimate the steady state conditions and elimination kinetics of folate in RBCs. DESIGN: Data from 2 randomized, placebo-controlled, double-blind intervention trials were used for kinetic modeling. These studies were performed to investigate the appearance of folate in RBCs in healthy women of childbearing age after different supplementation strategies (study 1: n = 69; 400 microg folic acid/d and 416 microg [6S]-5-methyltetrahydrofolate/d for 24 wk; study 2: n = 21; 800 microg folic acid/d for 16 wk). RESULTS:For RBC folate concentrations, steady state conditions were not reached after 24 (study 1) and 16 (study 2) wk of folate supplementation. However, with the use of these data, we calculated the biological half-life (t(1/2)) of RBC folate to be approximately 8 wk. With the application of pharmacokinetic principles, steady state conditions for RBC folate should be reached after 40 wk (t(1/2) x 5). CONCLUSION: With the use of pharmacokinetic principles, the appearance and elimination kinetics of RBC folate can be calculated on the basis of this t(1/2) value.
RCT Entities:
BACKGROUND: A maternal red blood cell (RBC) folate concentration > 906 nmol/L is thought to be optimal for lowering the risk of neural tube defects (NTDs) in pregnancy. Whereas the appearance of folate in RBCs has been followed during folic acid supplementation, data on elimination kinetics are not yet available. OBJECTIVE: The aim of our investigation was to estimate the steady state conditions and elimination kinetics of folate in RBCs. DESIGN: Data from 2 randomized, placebo-controlled, double-blind intervention trials were used for kinetic modeling. These studies were performed to investigate the appearance of folate in RBCs in healthy women of childbearing age after different supplementation strategies (study 1: n = 69; 400 microg folic acid/d and 416 microg [6S]-5-methyltetrahydrofolate/d for 24 wk; study 2: n = 21; 800 microg folic acid/d for 16 wk). RESULTS: For RBC folate concentrations, steady state conditions were not reached after 24 (study 1) and 16 (study 2) wk of folate supplementation. However, with the use of these data, we calculated the biological half-life (t(1/2)) of RBC folate to be approximately 8 wk. With the application of pharmacokinetic principles, steady state conditions for RBC folate should be reached after 40 wk (t(1/2) x 5). CONCLUSION: With the use of pharmacokinetic principles, the appearance and elimination kinetics of RBC folate can be calculated on the basis of this t(1/2) value.
Authors: Adila Prasodjo; Christine M Pfeiffer; Zia Fazili; Yingying Xu; Stacey Liddy; Kimberly Yolton; David A Savitz; Bruce P Lanphear; Joseph M Braun Journal: Ann Epidemiol Date: 2014-04-24 Impact factor: 3.797
Authors: Lisa A Houghton; Andrew R Gray; Meredith C Rose; Jody C Miller; Nicola A Hurthouse; Jesse F Gregory Journal: Am J Clin Nutr Date: 2011-05-18 Impact factor: 7.045
Authors: Meng-Yu Chen; Charles E Rose; Yan Ping Qi; Jennifer L Williams; Lorraine F Yeung; Robert J Berry; Ling Hao; Michael J Cannon; Krista S Crider Journal: Am J Clin Nutr Date: 2019-05-01 Impact factor: 7.045
Authors: Verne Tsang; Rebecca C Fry; Mihai D Niculescu; Julia E Rager; Jesse Saunders; David S Paul; Steven H Zeisel; Michael P Waalkes; Miroslav Stýblo; Zuzana Drobná Journal: Toxicol Appl Pharmacol Date: 2012-08-31 Impact factor: 4.219
Authors: Cinzia Scambi; Lucia De Franceschi; Patrizia Guarini; Fabio Poli; Angela Siciliano; Patrizia Pattini; Andrea Biondani; Valentina La Verde; Oscar Bortolami; Francesco Turrini; Franco Carta; Ciro D'Orazio; Baroukh M Assael; Giovanni Faccini; Lisa M Bambara Journal: PLoS One Date: 2009-03-11 Impact factor: 3.240
Authors: Mareile Niesser; Hans Demmelmair; Thea Weith; Diego Moretti; Astrid Rauh-Pfeiffer; Marola van Lipzig; Wouter Vaes; Berthold Koletzko; Wolfgang Peissner Journal: PLoS One Date: 2013-02-14 Impact factor: 3.240